NCT07073547View on ClinicalTrials.gov

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

June 19, 2028

Study Completion Date

June 19, 2028

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

AZD0120

AZD0120 is a BCMA/CD19 dual CAR T cell product under investigation for early-line treatment in subjects with multiple myeloma

Trial Locations (8)

10016

RECRUITING

Research Site, New York

33612

NOT_YET_RECRUITING

Research Site, Tampa

37203

RECRUITING

Research Site, Nashville

63110

NOT_YET_RECRUITING

Research Site, St Louis

75235

NOT_YET_RECRUITING

Research Site, Dallas

77030

NOT_YET_RECRUITING

Research Site, Houston

80218

RECRUITING

Research Site, Denver

91010

RECRUITING

Research Site, Duarte

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY